The purpose of this study is to compare the effects of an investigational medication, given at two different doses, either alone or in combination with another investigational medication for advanced metastatic melanoma. Melanoma is a type of skin cancer that can spread to other parts of the body. This study investigates which treatment option is safer and more effective in improving progression-free survival, which is the length of time during and after treatment that a patient lives with the disease without it getting worse.

Participants in the study will receive either the investigational medication alone or in combination with another investigational medication. The study procedures will involve regular monitoring to assess the effects of the treatments on progression-free survival.

• Who can participate: This study is for patients diagnosed with advanced metastatic melanoma. Participants must meet specific health criteria to be eligible, including age requirements.
• Study details: Participants will receive either ipilimumab alone or in combination with interferon alfa-2b. The study will involve regular health assessments to monitor the effects of the treatment. If applicable, participants may receive a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.